Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence. by Ianniciello, Angela et al.
Oncotarget96984www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 57), pp: 96984-96992
Chronic myeloid leukemia progenitor cells require autophagy when 
leaving hypoxia-induced quiescence
Angela Ianniciello1,*, Pierre-Yves Dumas1,*, Claire Drullion1,*, Amélie Guitart1, 
Arnaud Villacreces1, Yan Peytour1, Jean Chevaleyre1,5, Philippe Brunet de la 
Grange1,5, Isabelle Vigon1, Vanessa Desplat1, Muriel Priault2, Persio Dello Sbarba3, 
Zoran Ivanovic1,5, François-Xavier Mahon4 and Jean-Max Pasquet1
1Cellules Souches Hématopoïétiques Normales et Leucémiques, INSERM U1035 BMGIC, Université de Bordeaux, 33076 
Bordeaux Cedex, France
2UMR CNRS 5095, I.B.G.C, Université de Bordeaux, 33077 Bordeaux Cedex, France
3Department of Experimental and Clinical Biomedical Sciences, Università degli Studi di Firenze, 50134 Firenze, Italia
4INSERM U1218, Institut Bergonié, 33076 Bordeaux, France
5Etablissement Français du Sang Aquitaine-Limousin, 33075 Bordeaux, France
*These authors contributed equally to this work
Correspondence to: Jean-Max Pasquet, email: jean-max.pasquet@inserm.fr
Keywords: chronic myeloid leukemia, autophagy, stem cell
Received: September 01, 2016    Accepted: June 17, 2017    Published: June 30, 2017
Copyright: Ianniciello et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Albeit tyrosine kinase inhibitors anti-Abl used in Chronic Myeloid Leukemia (CML) 
block the deregulated activity of the Bcr-Abl tyrosine kinase and induce remission 
in 90% of patients, they do not eradicate immature hematopoietic compartments 
of leukemic stem cells. To elucidate if autophagy is important for stem cell survival 
and/or proliferation, we used culture in low oxygen concentration (0.1% O2 for 
7 days) followed back by non-restricted O2 supply (normoxic culture) to mimic stem 
cell proliferation and commitment. Knockdown of Atg7 expression, a key player in 
autophagy, in K562 cell line inhibited autophagy compared to control cells. Upon 7 
days at 0.1% O2 both K562 and K562 shATG7 cells stopped to proliferate and a similar 
amount of viable cells remained. Back to non-restricted O2 supply K562 cells proliferate 
whereas K562 shATG7 cells exhibited strong apoptosis. Using immunomagnetic 
sorted normal and CML CD34+ cells, we inhibited the autophagic process by lentiviral 
infection expressing shATG7 or using a Vps34 inhibitor. Both, normal and CML CD34+ 
cells either competent or deficient for autophagy stopped to proliferate in hypoxia. 
Surprisingly, while normal CD34+ cells proliferate back to non restricted O2 supply, 
the CML CD34+ cells deficient for autophagy failed to proliferate. All together, these 
results suggest that autophagy is required for CML CD34+ commitment while it is 
dispensable for normal CD34 cells. 
INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal 
malignant hematopoietic disorder characterized by the 
presence of a t(9;22)(q34;q11) reciprocal translocation 
[1, 2]. The BCR-ABL hybrid gene, the molecular 
hallmark of CML [3] encodes an oncogenic fusion protein 
harboring a deregulated tyrosine kinase activity that is 
responsible for leukemogenesis in vitro and in vivo [4, 5]. 
Development of ABL1 tyrosine kinase inhibitors (TKI) in 
the past decade provided the proof of concept that targeted 
therapies are an attractive strategy in CML. TKI imatinib 
is now the front-line therapy of CML in chronic phase, and 
competes with ATP for binding to the Abl kinase domain. 
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Because imatinib resistance has been a well-recognized 
problem, particularly in the advanced phase of the disease, 
new TKI have been developed. Nilotinib and dasatinib, the 
second-generation TKI, have been developed to override 
primary and secondary resistance [6, 7]. 
Hematopoietic stem cells (HSC) perpetuate a 
continuous stream of differentiated blood cells. In CML, 
the transformed HSC called leukemic stem cells (LSC) 
initiate and sustain the disease. Currently, the remaining 
questions are how to avoid TKI therapy for all life and 
how to eradicate the disease. Most of LSC reside in 
hematopoietic niches with peculiar biophysical conditions 
that preserve them. Indeed, the concentrations of oxygen 
in the organism are very different from the atmospheric 
concentration and varies according to the tissues [8]. 
The hematopoietic niche is characterized by low oxygen 
concentrations ranging from 4 to 0.1% [9–11]. TKI used 
in CML patient treatment are not able to eliminate these 
CSL and treatment abortion is followed by 60% of relapse 
[12–14]. Several studies reported that targeting other 
pathways in combination with TKI treatment could be 
efficient enough to target LSC. Among these interesting 
pathways, the inhibition of autophagy has been reported 
to be deleterious on leukemia and on the LSC reservoir 
[15]. This interesting result has led to propose preclinical 
and clinical trials in CML using autophagy inhibitors. To 
date, results are disappointing while all previous studies 
were very encouraging. Indeed, autophagy is involved in 
degradation of long life components  or organelles. It is 
triggered by stress conditions like nutriment starvation and 
used a complex machinery involving ATG proteins [16, 17].
We aimed at investigating if autophagy is required 
when stem cells leave the hematopoietic niche and if this 
requirement is similar between normal and CML cells. To 
answer this, we employed a strategy in which cells are 
placed for 7 days at low concentration of oxygen allowing 
slow cycling (LC1) and then replaced at atmospheric 
oxygen concentration leading to proliferation (LC2) [18]. 
RESULTS 
Inhibition of autophagy did not alter viable 
cell number and level of apoptosis in CML cell 
culture incubated at low O2 concentration
We used the K562 CML cell line in which a control 
shRNA (KS shCont) or a shRNA against the protein ATG7 
(KS shATG7) were expressed through virus infection. 
Inhibition of ATG7 expression was confirmed by western 
blotting and the consequent inhibition of autophagy in 
K562 shATG7 was verified by detecting the conversion 
of microtubule-associated light chain 3B-I in LC3B-II by 
western-blotting (Figure 1B). According to the procedure 
described by Giuntoli et al. [18] (Figure 1A), the two cell 
lines were cultured at 0.1% O2 (hypoxia) for 7 days (LC1). 
Compared to day 0, both cell lines underwent numerical 
decrease over incubation and significant increase of 
apoptosis at day 7 (Figure 1C and 1D, LC1). 
Inhibition of autophagy reduce numerical 
expansion and enhance apoptosis of CML cells 
following transfer to growth-permissive cultures 
in atmosphere O2 concentration
Back to atmosphere O2 concentration (Figure 1C, 
LC2), culture repopulation by either cell line exhibited a 
long lag phase.  At day 14, KS shCont cells repopulated 
cultures significantly more efficiently than KS shATG7 
cells. KS shATG7 cells exhibited significantly higher 
levels of apoptosis than control cells (Figure 1D, LC2). 
Thus, blocking autophagy in the K562 CML cell line 
strongly impaired proliferation and viability in normoxic 
LC2 of cells rescued from hypoxic LC1.
CML CD34+ progenitor cells stop cycling in 
hypoxia
We next explored if the requirement of autophagy 
of CML cells is also required for primary CML CD34+ 
cells harvested ex vivo. We used lentiviral infection to 
inhibit expression of ATG7 in immunopurified CD34+ 
CML cells. The plasmid used benefits from a GFP reporter 
gene allowing to gate cells expressing GFP to select cells 
expressing shATG7. Four days after the infection, flow 
cytometry, performed in 6 separate experiments, revealed 
a GFP+ cell population between 40 and 60%  (Figure 2A). 
To confirm the efficiency of shATG7 expression, GFP+ 
and GFP- cells were sorted and used for the detection 
of the conversion of microtubule-associated light chain 
3B-I in LC3B-II by western blotting (Figure 2B). GFP- 
and GFP+ cells were placed at low O2 concentration for 
7 days (Figure 2C and 2D, LC1) and then transferred to 
growth-permissive cultures incubated in atmosphere O2 
concentration (Figure 2C and 2D, LC2). Upon 7 days of 
hypoxia, a large majority of CD34+ CML cells, was low 
cycling, as determined via the detection of the proliferation 
marker Ki-67 (Supplementary Figure 1A, LC1). Viable 
cell number and level of apoptosis for CML CD34+ cells 
(Figure 2C and 2D, LC1) behaved like in the case of 
K562 cells (Figure 1C and 1D, LC1). In atmosphere O2 
concentration, CD34+ CML cells exhibited a kinetics of 
LC2 repopulation more prompt (no lag phase) than that of 
K562 cells (Figure 2C vs Figure 1C, LC2). In LC2, GFP+ 
cells underwent a significantly lower expansion and higher 
apoptosis levels than GFP- cells (Figure 2C and 2D, LC2). 
To avoid artefactual apoptosis linked to virus infection 
and ShRNA expression we performed similar experiments 
using control ShRNA which  show no effect on apoptosis 
(Supplementary Figure 1B).  These results emphasized 
those obtained for K562 shATG7 cells.  In GFP+ and GPP- 
CD34+ CML cells, expression of BCR/Abl protein was 
suppressed in hypoxia and re-expressed following transfer 
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to atmosphere O2 concentration (Supplementary Figure 
1C), as already reported [18, 19]. Because autophagy 
appeared requiring for proliferation of CML cells 
following transfer to atmosphere O2 concentration, we 
tried to confirm this finding by colony assay. Cells were 
seeded in methylcellulose at days 0, 7 (LC1) and 14 (LC2) 
in 3 separate experiments and the colonies counted on four 
fields after 10 days of incubation. The results obtained 
indicated that the generation of colony-forming cells was 
progressively reduced during cell population expansion in 
LC2 and that the impairment of autophagy significantly 
enhanced this reduction (Supplementary Figure 2).
Inhibition of autophagy in normal CD34+ cells 
neither change quiescence nor proliferation and 
viability back to atmosphere O2 concentration
Because both in vitro and ex vivo results suggested 
that autophagy is required for the full maintenance of LC2 
repopulation ability of CML cells incubated in hypoxia, 
we asked whether it also plays a critical role in normal 
CD34+ cells. Normal CD34+ cells were purified from 
leukoreduction filters as described Peytour et al [20]. Four 
days after infection, normal CD34+ cells were analyzed for 
GFP expression and between 35 and 50% of GFP+ cells 
were detected in 3 independent experiments (Figure 3A). 
To confirm the efficiency of shATG7, GFP- and GFP+ cells 
were sorted and used for detection by western blotting 
of the conversion of microtubule-associated light chain 
3B-I in LC3B-II (Figure 3B). In addition, inhibition of 
autophagy was also checked by incubating GFP- and GFP+ 
cells in minimal medium HBSS and conversion of LC3 
was detected by western-blot (Supplementary Figure 3A). 
Cells were then processed like in the experiments relative 
to CML cells (Figures 1 and 2).  Like CD34+ CML cells, 
normal CD34+ cells incubated at low O2 concentration for 
7 days promptly repopulated normoxic LC2 with no lag 
phase (Figure 3C, LC2). In contrast to CML cells, normal 
cells did not exhibit any significant difference between 
GFP+ and GFP- cells (Figure 3D, LC2). These results were 
emphasized by colony formation assay (Supplementary 
Figure 3B). This different behaviour is confirmed by 
Figure 1: Low oxygen concentration decrease proliferation of K562 cells. (A) K562 cells expressing a shRNA against luciferase 
(KS shCont) or a shRNA against ATG7 (K shATG7) were cultured at low O2 concentration (hypoxia 0.1% O2) for 7 days (LC1). Upon 
7 days, cells were replaced at atmospheric O2 concentration and grown until day 14 (LC2). (B) At day 0, 4 and 7, samples were proceed to 
analyze conversion of LC3B-I in LC3B-II by western-blot. (C) and (D) At indicated time, aliquot were analysed for cell count by trypan 
blue exclusion assay and apoptosis by flow cytometry using annexin V-APC labelling. Results are from at least 5 experiments. Significance 
between autophagy competent and deficient cells was quantitated using Wilcoxon test and show by an asterisk when p < 0.01.
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pharmacological inhibition of autophagy using a Vps34 
inhibitor in WT and CML CD34+ cells [21]. As shown 
in Supplementary Figure 3C, only CML CD34+ cells 
underwent apoptosis when Vps34 is blocked emphasizing 
autophagy requirement for CML commitment.
DISCUSSION
HSC immaturity and commitment has been linked to 
an oxygen gradient in bone marrow [9, 22]. Self-renewal 
and multipotency are key properties of HSC, allowing to 
sustain life-long blood cell production. In addition to many 
canonical pathways controlling self-renewal, autophagy 
has been reported to be critical for blood cell production, 
as deletion of ATG7 depleted the HSC compartment [23]. 
However, the same study reports that ATG7 requirement 
is not observed when foetal liver HSC have been used to 
reconstitute hematopoiesis. In CML, autophagy protects 
leukemic cells as it decreases the efficiency of imatinib, 
so the combination of autophagy inhibition with imatinib 
enhances CML cell death [15]. In addition, it was reported 
that primary CML cells, including LSC, are killed when 
autophagy is inhibited [15, 24, 25]. However, to eradicate 
LSC, it is necessary to deplete hematopoietic niches from 
leukemic quiescent cells which are able to commit and 
proliferate. By using low O2 concentration, we were able to 
reduce cycling enough on both cell lines and CD34+ cells. 
In our hands, 0.1% O2 during 7 days inhibits proliferation 
of a huge proportions of either cell lines or CD34+ cells, 
which is commonly described [26]. Placing hematopoietic 
Figure 2: CML CD34+ cells deficient for autophagy have impaired proliferation and show apoptosis back to atmospheric 
O2 concentration. (A) CML CD34+ cells were transduced with a shRNA against ATG7 and analyzed by flow cytometry to determine 
the percent of GFP- and GFP+ population. (B) Upon cell sorting, GFP- and GFP+ cells were lyzed and autophagy operating mechanism 
was check by detecting the conversion of microtubule associated light chain 3B-I in LC3B-II.  CD34+ cells were cultured at low O2 
concentration (0.1% O2) for 7 days (LC1). Upon 7 days, cells were replaced at atmospheric O2 concentration and grown until day 14 (LC2). 
(C) and (D) At indicated time, aliquot were analysed for cell count by trypan blue exclusion assay and apoptosis by flow cytometry using 
annexin V-APC labelling on the two population GFP– and GFP+. Results are from at least 6 experiments. Significance between autophagy 
competent and deficient cells was quantitated using Wilcoxon test and show by an asterisk when p < 0.01.
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cells at low O2 concentration decrease metabolism which 
shift from oxydation to glycolysis. At this stage autophagy 
do not seems to be required or critical. 
When cells are back to atmospheric O2 concentration, 
an oxidative burst occurred. All mechanisms participating 
to the cell cycle, DNA replication and expression of a large 
number of proteins involved in cell replication, require to 
refill all the reserves, and autophagy may be crucial at 
this step for CML cells. In addition, autophagy can afford 
protection from oxidative stress in CML cells [15, 27]. 
However, proliferation of normal CD34+ cells is similar 
for autophagy-competent or -deficient cells. This result 
suggests that autophagy is dispensable or stress may be 
overcame by other mechanisms in normal cells. Indeed, 
autophagy is also controlling the number of mitochondria 
(mitophagy) and in ATG7 deficient CD34+ CML  cells the 
accumulation of damaged organelles may kill the cell. 
In fact, the metabolic adaptation to the atmospheric O2 
concentration of normal CD34+ cells may still compensate 
for increasing request by an enhanced energy production, 
while in CD34+ CML cells, autophagy may be required to 
avoid damages [23]. We and other observed that Bcr-Abl 
protein expression decreased in hypoxia both in CML cell 
line or CD34+ CML progenitors. The decrease of protein 
translation in hypoxia is a well known cell response linked 
to quiescence even not yet fully understood [28–30]. 
However, for CD34+ CML cells autophagy is required 
when leukemic cells repopulate and reexpressed normal 
protein level as seen for Bcr-Abl. It will be interesting 
to check if supplying some metabolites may correct 
Figure 3: Normal CD34+ progenitor cells proliferate and show low apoptosis back to atmospheric O2 concentration. 
(A) Normal CD34+ cells were transduced with a shRNA against ATG7 and analyzed by flow cytometry to determine the percent of GFP- and 
GFP+ population. (B) Upon cell sorting, GFP- and GFP+ cells were lyzed and autophagy operating mechanism was check by detecting the 
conversion of microtubule associated light chain 3B-I in LC3B-II. CD34+ cells were cultured at low O2 concentration (0.1% O2) for 7 days 
(LC1). Upon 7 days, cells were replaced at atmospheric O2 concentration and grown for seven more days (LC2). (C and D)  At indicated 
time, aliquot were analyzed for cell count by trypan blue exclusion assay and apoptosis by flow cytometry using annexin V-APC labelling 
on the two population GFP- and GFP+. Results are from at least 4 experiments. Significance between autophagy competent and deficient 
cells was quantitated using Wilcoxon test.
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this defect or in an opposite way if starvation of one 
metabolite is deleterious. As previously reported in acute 
leukemia, addiction to a metabolite like glutamine may be 
partially circumvented by autophagy when leukemic cells 
proliferate [31]. 
Indeed, CD34+ CML cells leaving low O2 
environment may require strong energy adaptation to be 
able to repopulate. It is well known that hypoxia regulates 
mTor, itself regulatory negatively autophagy [32, 33]. 
What we observed could be an indirect consequence of 
hypoxia. At 0.1% of O2, both normal and leukemic cells 
cycle slowly and reduce metabolism intensity. They 
consume a lot of glucose and its concentration decreases 
enough inducing autophagy through AMPK and mTor-
induced phosphorylation of ULK1 [34, 35]. In autophagy-
deficient CD34+ CML cells, this may occur similarly 
without inducing autophagy. Back to non-restricted 
atmospheric O2 supply these cells encounter the most 
difficulties to repopulate. In contrast, in normal CD34+ 
cells this needs may not be required or may be overcame.
Indeed, autophagy requirement when LSC commits 
may well explain why the inhibition of autophagy in CML 
patients does not bring a real benefit since this affect only 
cells that will engage. One possibility to target the CML 
LSC will be thus to mobilize stem cells in combination 
with the inhibition of autophagy. HSC seems to be not 
addicted to autophagy when they engage. This will be a 
benefit for HSC but deleterious to LSC. Pharmacological 
autophagy inhibitors recently reported could be a very 
important way. 
In conclusion, tracking autophagy deserves to pay 
attention but should be considered in combination to stem 
cell mobilizing agent to be able to target different steps of 
commitment and stem cell population in CML and then 
applied to other leukemia. 
MATERIALS AND METHODS
Reagents
RPMI 1640 medium, fetal calf serum (FCS), 
phosphate buffered saline (PBS), were from Invitrogen. 
Trypan blue and the antibody against LC3 were from 
Sigma (St Quentin Fallavier, France). The following 
antibodies : ATG7 was from Cell Signalling (Danvers, 
USA), and Hsp60 was from Santa Cruz (Bergheimer, 
Germany). Annexin-V-APC was from Beckman coulter 
(Villepinte, France). Ki-67 antibody, control isotype and 
anti-Abl were purchased from BD (Becton Dickinson, 
France). PIK-III and SBI-0206965 were purchased from 
Selleck chemicals (Houston, USA).
Cell lines
The human Bcr-Abl positive K562 cell line used in 
this study was from the American Type Culture Collection 
(ATCC). Cells were maintained in RPMI 1640 medium 
supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL 
penicillin and 0.1 mg/mL streptomycin at 37°C in a 
humidified atmosphere containing 5 % CO2. Aliquots were 
taken at 24 h intervals for assessment of cell viability by 
Trypan blue exclusion. The shATG7 K562 cell line was 
generated as previously described [36]. 
CD34 cell isolation
All CML patient samples correspond to diagnosis 
when patients were in chronic phase with Ph chromosome 
and BCR-ABL-positive CML. Informed consent was 
obtained in accordance with the Declaration of Helsinki 
from all patients by the biological resource center (BRC 
N° EN-CRB-042). Retrospectively, all patients were 
responding to TKI. Mononuclear cells were isolated from 
bone marrow or blood by Ficol gradient. CD34+cells were 
purified using human CD34+ cell selection kit (Miltenyi 
Biotech, Germany) and purity was analyzed by flow 
cytometry using phycoerythrin-conjugated anti-CD34 
antibody (Becton Dickinson, France). Purified CD34+ 
positive cells were frozen in liquid nitrogen until use. For 
normal CD34+ cell, leukoreduction filters were provided 
by the Blood French institute of Bordeaux and flushed 
according to the procedure described by Peytour et al 
[37]. Cytokines and growth factors were from PeproTech 
(Neuilly sur Seine, France).
Culture at low or atmospheric oxygen 
concentration
As reported by Giuntoli et al, cells are placed at 
day zero (d0) at low oxygen concentration (0.1% LC1) 
for 7 days in a culture hood Xvivo System (BioSpherix, 
Ltd, USA) (Figure 1A) [18]. Upon 7 days (d7), cells were 
replaced at atmospheric oxygen concentration for 7 days 
until day 14. At day 0, 7 and 14, aliquots were analyzed 
for number cells and apoptosis.
Lentiviral production, titration, and cell 
transduction
Lentiviral particles were added to the target cells 
and incubated for 24 hours. Then, the cells were washed 
twice in PBS and grown in the presence of medium for 
6 days before experimental use. Cells in which targets 
had been silenced by shRNA (3 different sequences 
shRNA were tested for all targets) were sorted using GFP 
or DsRed expression, analyzed by flow cytometry as a 
homogenous cell population with purity above 98%. To 
confirm silencing of ATG7, specific protein expression 
was detected by western-blot. For CD34+ cells, infection 
was performed twice, two and one day before experiment 
in the presence of polybrene (8 µg/mL). Four days later, 
an aliquot of cells were analyzed by flow cytometry to 
Oncotarget96990www.impactjournals.com/oncotarget
measure the percent of infected cells and response to 
TKI was detected with annexin V-APC. Viability was 
calculated on both GFP+ and GFP- cell population. 
Western Blotting
Protein lysates were prepared according to Gioia 
et al [38]. Protein concentration was measured by the 
BCATM Protein Assay (Pierce, Rockford IL, USA) and the 
lysates were stored at –80°C. Equal amounts of protein 
were separated by electrophoresis on an SDS-PAGE 12.5 
or 15% and transferred to a pvdf membrane as described 
[39] (Biorad, Marnes-La-Coquette,France). After blocking, 
the membrane is incubated with primary antibodies 
and secondary antibodies. Protein–antibody complexes 
were detected by an enhanced chemiluminescence 
immunoblotting ECL (Perkin Elmer, Courtaboeuf, France).
Flow cytometry 
Cells (105 cells) were incubated for 10 min in 500 µl 
of Hepes/NaCl buffer with 2 mM Ca2+, 2µl of Annexin 
V- APC and 0.25 µg of propidium iodine (PI) before flow 
cytometry analysis on Facs Canto II. At least ten thousand 
events were acquired for statistical analysis. Detection 
of apoptosis by annexin V labeling was performed 
according to the manufacturer instructions (Biolegend). 
Ki-67 detection was performed on PFA-fixed cells after 
permeabilization for 5 min using 0.1% Triton X-100. 
Phycoeryhtrine-conjugated antibody against Ki-67 was 
incubated for 30 min at 1 µg/ml. After washing, pelleted 
cells were resuspended in Hepes/NaCl buffer and analyzed 
by flow cytometry. Phycoeryhtrine-conjugated Isotype 
was used as control.
Autophagy inhibition by RNA silencing of ATG7
To inhibit autophagy, HIV-1 lentivirus-based vectors 
were used to introduce shRNAs against luciferase or 
ATG7 as already reported [40]. To confirm autophagy 
inhibition by silencing of ATG7 cells were grown in 
nutrient deprived medium (HBSS) in the absence or in the 
presence of Bafilomycin A and both LC3B I and II form 
were detected by western-blot. 
Autophagy inhibition by PIK-III
PIK-III was dissolved in DMSO at 20 mM. Dose 
response experiment was performed to determine the 
concentration which inhibits autophagy with minimal 
apoptosis using K562 cells expressing the mCherry-GFP-
LC3 protein (Kindly provided by Dr Soengas, Madrid, 
Spain) [41]. K562 cells were incubated with 0, 0.3, 1 and 
3 µM of PIK-III and cells were analyzed by flow cytometry 
after annexin V-APC labelling. PIK-III increases GFP 
and mCherry fluorescence in a dose dependent manner 
and 1 µM was chosen as the concentration inhibiting 
autophagy with no significant apoptosis. 
Statistical analysis
A Wilcoxon test was used to calculate differences 
between means; differences were considered significant 
only when p ≤ 0.05 or 0.01 as indicated and shown by an 
asterisk *.
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